Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation of Schedule of Analyst meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 30, 2015. Fredun Pharmaceuticals Ltd - 539730 - Shareholding for the Period Ended November 26, 2021
Fredun Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended November 26, 2021. For more details, kindly Click here Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Allotment
Allotment of 1,96,635 Equity Shares to Promoters upon conversion of Warrants into equivalent number of Equity Shares. Fredun Pharmaceuticals Ltd - 539730 - Non-Applicability Of Regulation 23 (9) Of SEBI (LODR) Regulations, 2015 Regarding Submission Of Disclosures Of Related Party Transactions For The Half Year/ Year Ended 31St March, 2021
This is to certify that in order to comply with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 15 of Chapter IV of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the paid up equity share capital does not exceed Rs. 10 crores and the Net - worth does not exceed Rs. 25 crores as on last day of the previous financial year i.e. 31st March, 2021. Therefore our Company is not required to submit disclosures for related party transactions for the half year/year ended on 31st March, 2021. Kindly take the same on your records Thanking you, Fredun Pharmaceuticals Ltd - 539730 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nikhil Vora Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Allotment
Dear Sirs, This is with reference to the in-principle approval granted by your good office vide letter No. DCS/PREF/JR/PRE/1652/2021-22 dated November 17, 2021 Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at their meeting held on 17th November, 2021 at 6.30 pm has allotted 2,46,374 Equity Shares at a price of Rs. 422.10/- each and 2,16,771 Convertible Warrants at a price of Rs. 422.10/- each by way of Preferential Issue. The requisite details as required in terms of SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015 are provided at Annexure I. Further the meeting was concluded at 6:55 P.M. Kindly take the aforesaid information on your records. Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Newspaper Publication
In compliance to Regulation 47(1)(b) of SEBI Listing Regulations, 2015; we enclose herewith the copies of the Newspaper cuttings of the Financials Results of the Company for the Quarter ended September 30, 2021; as approved by the Board in its Meeting held on Saturday, November 6, 2021; published in Business Standard & Mumbai Lakshadeep newspaper(s) on November 8, 2021. Kindly take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Financial Results For The Quarter Ended 30Th September, 2021
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Saturday, 6th November, 2021 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended September 30, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 3:00 P.M. and concluded at 4.00 P.M. Kindly oblige and take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of The Board Meeting
We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Saturday, 6th November, 2021 at 3:00 pm had considered and approved the following items of Business: 1. In compliance to Regulation 30 and 33 of SEBI Listing Regulations, 2015; the Un-Audited Financial Results of the Company for the quarter ended September 30, 2021; along with the Limited Review Report as issued by M/s Savla & Associates; Statutory Auditors of the Company; copies of which are attached hereunder; The Meeting of the Board Commenced at 3:00 P.M. and concluded 4:00 P.M. Kindly oblige and take the same on your Records. Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Intimation for Unaudited Financial Results Alonwith Statement Of Asset And Liability, Limited Review Report And Cash Flow Statement For The Quarter And Half-Year Ended 30Th September, 2021
Fredun Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Saturday, 06th November 2021 at 3:00 P.M. at the Registered Office of the Company to transact inter-alia the following businesses: 1. To discuss, consider and approve Unaudited Financial Results of the Company for the Quarter and Half Year ended September 30, 2021; 2. Any other matter with the permission of the Chair. Kindly take the same on your Records.